8-K: Spruce Biosciences Announces Full Year 2023 Results, Provides Clinical Trial Updates and Implements Cost Reduction Plan

Spruce Biosciences reported its 2023 financial results, provided updates on its clinical trials, and announced a cost reduction plan including a workforce reduction and termination of a clinical trial.

Summary

• Spruce Biosciences announced its full year 2023 financial results and provided updates on its clinical programs.
• The CAHmelia-203 study of tildacerfont in adult classic CAH did not meet its primary efficacy endpoint, showing a -2.6% placebo-adjusted reduction in androstenedione (A4) at week 12, which was not statistically significant.
• The CAHptain-205 study in pediatric classic CAH showed positive results, with 73% of patients achieving a reduction in A4 or glucocorticoid (GC) at 12 weeks.
• The company plans to continue dose-ranging in the CAHptain study and expects topline results from the CAHmelia-204 study in the third quarter of 2024.
• Spruce is implementing a cost reduction plan, including terminating the CAHmelia-203 study and reducing its workforce by approximately 21%, which is expected to cost $0.4 million.
• The company's cash and cash equivalents were $96.3 million as of December 31, 2023, and they expect the cost reductions to extend their cash runway through the end of 2025.
• Collaboration revenue for 2023 was $10.1 million, primarily from a partnership with Kaken Pharmaceutical.
• Research and development expenses for 2023 were $49.4 million, and the net loss for the year was $47.9 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the failure of the CAHmelia-203 study and the workforce reduction, although there are some positives from the pediatric study and the extended cash runway.

Positives

• The CAHptain-205 study in pediatric patients showed positive results with 73% of patients achieving a reduction in A4 or GC.
• The company has extended its cash runway through the end of 2025 due to cost reduction measures.
• Spruce Biosciences has a collaboration agreement with Kaken Pharmaceutical, generating $10.1 million in revenue in 2023.
• Tildacerfont was generally safe and well-tolerated in both the adult and pediatric studies.

Negatives

• The CAHmelia-203 study in adult patients did not meet its primary efficacy endpoint.
• The company is implementing a workforce reduction of approximately 21%.
• The company is terminating the CAHmelia-203 study.
• Compliance with study medication and glucocorticoid (GC) was low in the CAHmelia-203 study, with only 50% of patients reporting 80% or greater compliance.

Risks

• The failure of the CAHmelia-203 study to meet its primary endpoint raises concerns about the efficacy of tildacerfont in adult patients with severe hyperandrogenemia.
• The workforce reduction may impact the company's ability to execute its clinical programs.
• The company's estimates for costs associated with the realignment plan are preliminary and may differ materially from actual costs.
• The company's future success depends on positive results from the CAHmelia-204 and CAHptain-205 studies.
• There is a risk that the company may not receive regulatory approval for tildacerfont.

Future Outlook

The company anticipates topline results from the CAHmelia-204 study in the third quarter of 2024 and from additional dose-ranging in the CAHptain study in the fourth quarter of 2024. They plan to meet with the FDA in early 2025 to discuss the registrational program for tildacerfont. The company expects its cost reduction plan to extend its cash runway through the end of 2025.

Management Comments

• Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, stated that they are grateful to all the patients, families, study team and investigators who supported the CAHmelia-203 clinical trial.
• Dr. Szwarcberg noted that the CAHmelia-203 study provided important data that will inform ongoing development of tildacerfont in adult classic CAH.
• Dr. Szwarcberg mentioned that they are eager to report topline results from CAHmelia-204 in the third quarter of 2024.
• Dr. Szwarcberg stated that the company has made the difficult but necessary decision to streamline operations and implement cost reduction measures, which has extended their cash runway through the end of 2025.

Industry Context

This announcement comes as the biopharmaceutical industry faces increasing pressure to manage costs and demonstrate clinical efficacy. The mixed results from Spruce's clinical trials highlight the challenges in developing treatments for rare endocrine disorders. The company's decision to prioritize resources and reduce costs is a common response to clinical trial setbacks and financial pressures in the biotech sector.

Comparison to Industry Standards

• The failure of the CAHmelia-203 study to meet its primary endpoint is a setback, as many companies in the rare disease space face similar challenges in demonstrating efficacy in difficult-to-treat patient populations.
• The positive results from the CAHptain-205 study are encouraging, as they suggest that tildacerfont may be effective in pediatric patients, which is a key area of unmet need in CAH.
• The cost reduction measures implemented by Spruce are similar to actions taken by other biotech companies facing clinical trial setbacks or financial constraints, such as layoffs and program terminations.
• Companies like Crinetics Pharmaceuticals and Neurocrine Biosciences are also developing treatments for endocrine disorders, and their clinical trial results and financial performance are closely watched by investors in this space.
• The collaboration with Kaken Pharmaceutical is a common strategy for biotech companies to expand their reach and access funding, similar to partnerships seen in the industry.

Stakeholder Impact

• Shareholders may be concerned about the failure of the CAHmelia-203 study and the workforce reduction.
• Employees are impacted by the workforce reduction, with approximately 21% of the workforce being terminated.
• Patients and families may be hopeful about the positive results from the CAHptain-205 study, but also concerned about the termination of the CAHmelia-203 study.
• The company's suppliers and creditors may be impacted by the cost reduction measures.

Next Steps

• The company plans to continue dose-ranging in the CAHptain study.
• Topline results from the CAHmelia-204 study are expected in the third quarter of 2024.
• Topline results from additional dose-ranging in the Phase 2 CAHptain clinical trial are expected in the fourth quarter of 2024.
• The company plans to meet with the FDA in early 2025 to discuss the registrational program for tildacerfont.

Key Dates

Keywords

Spruce Biosciences, tildacerfont, CAH, Congenital Adrenal Hyperplasia, clinical trial, hyperandrogenemia, androstenedione, glucocorticoid, cost reduction, workforce reduction, FDA, regulatory approval